Short Interest in Aptorum Group Limited (NASDAQ:APM) Increases By 70.4%

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 4,600 shares, a growth of 70.4% from the October 15th total of 2,700 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 19,700 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. bought a new position in shares of Aptorum Group Limited (NASDAQ:APM) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned about 0.27% of Aptorum Group at the end of the most recent quarter. 3.80% of the stock is currently owned by institutional investors and hedge funds.

Aptorum Group Trading Down 38.0 %

APM traded down $0.42 during trading on Friday, hitting $0.68. The company had a trading volume of 214,931 shares, compared to its average volume of 703,346. Aptorum Group has a one year low of $0.64 and a one year high of $17.49. The firm’s 50-day moving average price is $1.85 and its 200 day moving average price is $3.28.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.